Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Earnings

Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled

Total assets under management for Novo Holdings, Novo Nordisk’s controlling shareholder, fell by more than one-third last year. The report caps off a tumultuous year for the Novo group of companies.

March 12, 2026

1 min read

Annalee Armstrong

Magnifier magnifying exclamation mark on red background. Alert and precaution concept. Caution and risk management security signal announcement hazard and dangerous notice symbol

Weight loss

Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.

March 12, 2026

2 min read

Tristan Manalac

Fashionable halftones collage. Startup business concept,fast business startup. Trendy modern retro illustration in bright trendy colors. Strategic planning concept and business success. Vector illustration

Rare diseases

BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug

Data from BridgeBio Pharma’s Phase 3 FORTIFY study show that BBP-418 significantly increases levels of a key disease biomarker that helps stabilize muscles in patients with limb-girdle muscular dystrophy.

March 12, 2026

2 min read

Tristan Manalac

Vertical collage image of black white effect arm hold tied arrow shoot down darts board target isolated on painted background.

Clinical research

MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular dystrophy.

March 12, 2026

3 min read

Tristan Manalac

Businessman carrying big bag of money moving forward

C-suite

J&J, AbbVie CEOs See Pay Spike to More Than $30M

The chief executives of AbbVie and Johnson & Johnson are now among the highest-paid pharma leaders after pay bumps pushed their 2025 compensations past $30 million.

March 12, 2026

1 min read

Tristan Manalac

Insights

From Two Trials to One, Sponsors Face a Higher Standard

In this episode of Denatured, you’ll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of product management for risk-based quality management at eClinical Solutions. We speak about how the FDA’s latest decision to have one, rather than two pivotal studies, for new drug applications raises the bar for data collection and risk-based management.

March 12, 2026

1 min read

Jennifer C. Smith-Parker

Downtown Cityscape Los Angeles, California, USA

Job Trends

The Next Cambridge? LA Sets Its Sights Higher

The Los Angeles region is one of California’s fastest-growing life sciences hubs, according to a California Life Sciences sector report. The CEO of BioscienceLA discusses the market’s strengths, challenges and where it might be five years from now.

March 12, 2026

5 min read

Angela Gabriel

Hiring collage showing HR checking applicant information

Job Trends

Hiring Outlook: February Brings First YOY Job Increase Since 2022

Last month, for the first time in nearly four years, average job postings live on BioSpace did not decline year over year. In another encouraging sign, the number of biopharmas letting employees go fell.

March 12, 2026

4 min read

Angela Gabriel